Roche, Transgene Sign Vaccine Pact | Chemical & Engineering News
Volume 85 Issue 16 | p. 24 | Concentrates
Issue Date: April 16, 2007

Roche, Transgene Sign Vaccine Pact

Department: Business

Roche and French biotechnology company Transgene will collaborate to develop products from Transgene's therapeutic vaccine program against diseases mediated by the human papilloma virus. HPV is associated with the development of precancerous lesions and cancer of the cervix. Under the agreement, Roche will fund worldwide development of TG 4001, Transgene's lead vaccine candidate, which has completed Phase II studies and is in planning for Phase III studies. Transgene will receive $17 million up front and $13 million as a milestone payment related to the Phase III studies. Further payments to Transgene may top $250 million.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment